Penumbra, Inc. (PEN) Earnings Call Transcript & Summary

May 2, 2023

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 65 min

Earnings Call Speaker Segments

Jee Hamlyn-Harris

executive
#1

Thanks, operator, and thanks to everyone for being with us today as we go over Penumbra's earnings release for Q1 2023. You can find a copy of the press release along with the financial tables — including a reconciliation from GAAP to non-GAAP — under the Investors tab on our website, www.penumbrainc.com. On this conference call, the company will be making forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which cover statements about our financial performance, commercialization, clinical trials, regulatory status, quality compliance and business trends. Actual results might differ materially from what those forward-looking statements state or imply because of certain risks and uncertainties, such as those referenced in our 10-K for the year ended December 31, 2022, filed with the SEC. So we caution you not to place undue reliance on these forward-looking statements, and we encourage you to review our periodic filings with the SEC, including the 10-K just mentioned, for a fuller discussion of these factors and other risks that could affect our future results or the market price of our stock. Penumbra disclaims any duty to update or revise our forward-looking statements because of new information, future events, developments or otherwise. On this call, some financial measures are presented on a non-GAAP basis. The corresponding GAAP measures and a reconciliation of GAAP to non-GAAP financial measures appear in our posted press release. Adam Elsesser, Penumbra's Chairman and CEO, will give a business update. Maggie Yuen, our Chief Financial Officer, will then talk about our financial results for the first quarter. And Jason Mills, our Executive Vice President of Strategy, will go over our 2023 guidance. Sandra Lesenfants, our President of Interventional, will join the team for questions. With that, I'd like to hand the call over to Adam Elsesser.

Adam Elsesser

executive
#2

Thank you, Jee. Hello, everyone, and I appreciate you joining us for Penumbra's call covering the first quarter of 2023. Our Q1 total revenues reached $241.4 million, representing an 18.4% increase compared with the prior year on a reported basis, and a 19.7% gain in constant currency terms. Looking at it sequentially, revenue for the first quarter grew by $20 million — marking the largest dollar sequential increase our company has ever recorded, aside from the COVID-driven surge between the second and third quarters of 2020. The Lightning Flash rollout in Q1 exceeded our already elevated expectations, making it the most significant product introduction in our company's history, despite constrained supply throughout the quarter. Lightning Flash is driving faster growth in our U.S. Our vascular division grew 23% compared to the same period last year, and our U.S. vascular thrombectomy franchise rose 26% year-over-year during Q1. We're carrying that forward with the recent introduction of Lightning Bolt 7, and results from cases involving it have been very positive so far. Momentum has also picked up considerably in our ischemic stroke business, which leads the market, thanks to the releases of RED 72 featuring our proprietary inner SENDit technology, RED 43, and BMX81. As a result, we are lifting our 2023 revenue projection substantially, and we anticipate strong growth over the coming 5-plus years. Jason will share more specifics about our forecast later in this call. For Q1, gross margins matched what we had anticipated, and we look for gross margin improvement throughout 2023. Our goal remains reaching gross margins above 70% over the next several years. In the first quarter, non-GAAP operating income climbed to $10.4 million, equal to 4.3% of revenue, even with the payroll taxes and sales meeting costs that are typically higher early in the year. Given robust top-line growth, improving gross margins, and careful control of operating expenses, we anticipate a substantial rise in operating profits and cash flow during 2023 and afterward. Lightning Flash has reached a pivotal point in the thrombectomy sector. From what we have seen in the early launch, we are confident this product will reshape PE and venous thrombectomy, ultimately helping hundreds of thousands of patients—not only in 2023 but for a minimum of the next 5-plus years. In Q1, our U.S. PE and DVT procedure volumes rose over 30% compared to the prior quarter. Throughout those three months, case numbers picked up speed as more conversions away from rival mechanical thrombectomy offerings and lytic therapies toward Lightning Flash took hold. Heightened pull for Flash showed up among both newly acquired accounts and those we already had. As a matter of fact, most of them have placed additional Flash orders already, and the repeat order rate holds steady across new and existing accounts alike. Once more, because of how proprietary this technology is, how large the opportunity is, and where this field stands right now, we believe this momentum may run longer than what we'd typically see in one of our product launches. In April, several of the biggest hospital networks in the nation signed contracts for Lightning Flash, and that lets our team begin the hospital-by-hospital Value Analysis Committee review for Lightning Flash. For Penumbra, having Lightning Bolt 7 arrive just one quarter after Lightning Flash represents an unprecedented moment, and the same is true for U.S. patients undergoing thrombectomy. What physicians tell us about Lightning Bolt 7 has been extraordinary; and while it's still early, some doctors who previously would have chosen open surgery or resorted to lytics are already starting to convert to Lightning Bolt 7. Roughly 3 weeks ago, we saw a terrific illustration of what Lightning Bolt 7 can do. A patient came into the hospital suffering from severe leg pain along with necrotic toes. About 3 months before, that patient had received an SFA stent. A CT scan revealed a total blockage from the SFA through to the popliteal. An above-the-knee amputation had been scheduled for this patient; yet the physician — new to Penumbra's thrombectomy devices — had learned of Lightning Bolt 7 the day before. Before the planned surgery, he chose to give it a try. In roughly 2 minutes of device time, Lightning Bolt 7 removed the thrombus entirely, and in all likelihood the patient keeps her leg and her foot; thanks to this breakthrough technology, we have a rare chance to bring a large number of physicians over to Lightning Bolt 7 from traditional ways of addressing arterial thrombus; that said, we recognize plenty of work lies in front of us. Time will be required for this work, and our start has been excellent, among other things the hospital contracting and value analysis process for Flash that we referenced earlier. Hearing about the distinct wins that Lightning Flash and Lightning Bolt 7 have each racked up so far fires up our whole team enormously, pushing us to get these technologies into the hands of every doctor treating the more than 800,000 venous, PE and arterial patients across the United States. Beyond that, we've had successful launches in stroke, and we're fully aware of the significant enthusiasm among the physicians we serve — enthusiasm that has spread into the investment community too. Naturally, we feel that same excitement. That said, let me step back from the short term and note that for the next 5-plus years, this effort will be our primary focus. With that emphasis in mind, we think these remarkable proprietary technologies will reach a substantial share of those patients. The components needed to carry out our plans are important. They involve continuing to expand production capacity so rising demand can be satisfied, demonstrating value to hospital clients, increasing physician understanding and instruction, and generating further clinical proof. Every one of our functional groups — spanning R&D, regulatory, manufacturing, marketing, clinical, commercial, and national accounts — has transformed dramatically over the last 2 years and is now fully prepared and concentrated on the work still to come; in our view, computer-orchestrated thrombectomy will flourish in the near term, will possess a long tail, and will emerge as the definitive paradigm in thrombectomy. Now to our neuro franchise. The pickup in our stroke segment, which rose 6% quarter over quarter in the U.S., came from the releases of RED 72, featuring our own SENDit inner catheter technology, along with RED 43; these offerings mark substantial strides in the trackability of aspiration catheters sized at 0.072 and in removing clots distally. As inventory of these 2 key products grows, we believe that combined with BMX81, which we launched not long ago, they will keep boosting our expansion and share of the neuro market, especially as doctors keep recognizing the trade-off tied to oversized aspiration catheters that have appeared on the market over the last several years. The significance of these newest product launches is substantial, since they create a firm foundation in advance of Thunderbolt, which is our computer-orchestrated platform for stroke. Turning now to our operations beyond the United States: we are proud of the results delivered by our global teams, which increased revenue by 8% compared with the prior quarter and elevated our international business to an annual revenue run rate exceeding $0.25 billion. Our excitement is even stronger regarding what the future holds over the next several years. We recently introduced our RED catheter for stroke, along with our first-generation computer-orchestrated thrombectomy offerings, Lightning 12 and 7, into Europe. In addition, we have added substantial expertise and capacity across our sales, regulatory and reimbursement teams overseas. Bottom line, our view is that in a little over three years, products like RED catheters and CAT RX can be brought together with the most sophisticated items we offer — Lightning Flash, Lightning Bolt 7 and Thunderbolt — for our global teams. Over that period, we expect a meaningful increase in sales and earnings for our businesses outside the U.S. There is also strong momentum in our Immersive Healthcare unit; we take real pride and feel genuine enthusiasm in reporting that we just entered a multiyear partnership with the Department of Veteran Affairs Office of Healthcare Innovation and Learning aimed at testing, jointly developing and expanding virtual reality tools for veterans in a range of care environments, the home included. The VHA's vision really stands out to us, along with how committed they are to giving veterans wider access to excellent care. Through this partnership, plus the other major projects we've got underway with big private health systems here in the United States, we're learning an enormous amount about all the different ways our technology can improve health care in areas like rehab, mental and cognitive health, and aging. At the same time, it's helping us figure out the business model needed to grow this operation over the coming years, which will ultimately pay off for a large number of patients. At this point, I'll turn things over to Maggie, who will walk through our financial results for Q1 2023.

Maggie Yuen

executive
#3

Thanks, Adam. Hello, everyone, and good afternoon. I'll go over our Q1 2023 financial performance today. For this quarter, revenue and gross margin figures are presented on a GAAP basis, whereas operating expenses and operating income are non-GAAP. You can find the matching GAAP figures and a GAAP-to-non-GAAP reconciliation in the press release we posted. Total revenues for the first quarter, which ended March 31, 2023, came to $241.4 million — up 18.4% as reported and 19.7% in constant currency versus the same period in 2022. Sales in the quarter broke down geographically as 71.2% from the U.S. and 28.8% from international markets. U.S. We saw a 19.1% rise on a reported basis, while our overseas markets were up 16.7% as reported and 21% when measured in constant currency. The 9.1% sequential improvement came mainly from powerful traction in our U.S. vascular thrombectomy operation. Now turning to revenue broken out by franchise. Our vascular segment brought in $142.8 million during the first quarter of 2023, which marks a 16.3% gain reported and 17.2% in constant currency versus the comparable period a year earlier. Global vascular revenue was chiefly fueled by robust expansion in the United States, where sales climbed 23% year-over-year, though this was partly offset by uneven results from international distributor regions relative to the same quarter last year. In the first quarter of 2023, our neuro business generated $98.5 million in revenue. That's up 21.5% as reported and 23.4% in constant currency versus the same period last year. The growth came from new product launches in the U.S., ongoing momentum in Europe, and favorable variability in international distributor region revenue compared with the same quarter a year ago. Now on to gross margin. For the first quarter of 2023, gross margin came in at 62.6%, versus 62.5% in the first quarter of 2022 and 62.6% in the prior quarter. The gross margin results reflected roughly a 1 point gain from a richer mix of vascular thrombectomy product sales, which was offset by higher start-up costs tied to several new product launches as well as regional mix. We're set to keep enhancing our margins all through 2023, and we anticipate ongoing beneficial shifts in product mix, gains in productivity, and better fixed cost leverage as volumes from new products keep speeding up over the remainder of the year. Turning now to non-GAAP operating expenses, which leave out amortization tied to acquired intangible assets—$2.4 million this quarter, $1.8 million last quarter, and $1.8 million in the same quarter a year ago. Operating expense totaled $140.7 million for the quarter, equal to 58.3% of revenue, versus $129.7 million, or 63.6% of revenue, in last year's comparable quarter. We've managed to scale the business efficiently while investing only minimally in headcount relative to a year ago. In the first quarter of 2023, R&D costs totaled $20 million, down from $20.6 million in the same period of 2022. Selling, general and administrative costs reached $120.7 million in Q1 2023, representing 50% of revenue, compared with $109.1 million, or 53.5% of revenue, in Q1 2022, and $113.3 million, or 51.2% of revenue, in the prior quarter. Seasonal expenses tend to run higher in the opening quarter of the year, but we continue to exercise discipline regarding discretionary spending. Operating income for Q1 2023 was $10.4 million, or 4.3% of revenue, whereas the year-ago comparable period produced an operating loss of $2.3 million. Moving on to cash flow and the balance sheet: we closed out the first quarter holding $199.1 million in cash, cash equivalents and marketable securities, up $11.1 million relative to the prior quarter. As profitability and working capital get better, we anticipate that favorable operating cash flow patterns will persist through the remainder of the year. At this point, I'll hand things over to Jason so he can walk everyone through our guidance.

Jason Mills

executive
#4

Appreciate that, Maggie, and hello everybody this afternoon. Turning to 2023, our revenue outlook is moving up to between $1.04 billion and $1.06 billion, reflecting growth of 23% to 25% compared with 2022 total revenue of $847.1 million. Previously, our guidance had set only a floor of $1 billion. On a year-over-year basis, we anticipate worldwide revenue growth rates will pick up speed throughout 2023, reaching the low 20% range during the second quarter and the mid- to high 20% range across the second half of 2023. When you look at the 23% to 25% year-over-year total revenue growth we're guiding to for 2023, our vascular segment should come in a bit above that, while neuro lands under it. Now, further down the P&L. As 2023 progresses, gross margin expansion is what we're anticipating, and our goal of surpassing 70% gross margins remains in place over the next few years. On top of that, our non-GAAP operating margin outlook is going up — we're now projecting better than 10% by year-end, and we anticipate additional operating margin improvement in the years that follow. At this point, I'll hand things back to Adam for his closing comments.

Adam Elsesser

executive
#5

Thanks, Jason, Maggie, and Jee. Obviously, we're incredibly thrilled about the Lightning Flash and LIGHTNING BOLT launches. Launches of this transformational kind are rare in the medical device space. We're also very excited regarding the product introductions within our stroke franchise. Alongside that excitement is a distinct appreciation, refined through decades of experience at our company, of the vital effort lying ahead across the coming several years to fully capitalize on this world-class technology and deliver it to each person who might benefit. Everyone on our team recognizes and grasps what lies ahead. My belief is that they're energized and prepared to perform that work so our physician customers and their patients are certain to have this technology. From all the team members I've talked with, each morning, they understand they must rise and attempt and attempt and attempt. Through that effort and the teamwork we've demonstrated, we will deliver the wave of computer-orchestrated aspiration to our customers globally. I believe they're ready. Thanks, and now we can open the call to questions.

Robbie Marcus

analyst
#6

Congratulations on a strong quarter. Perhaps to begin, I'd like to focus on the peripheral thrombectomy line, especially Flash. You provided a few figures there, but essentially, this is a 2-part inquiry. First, how do you view Flash's adoption with respect to market expansion as opposed to share gains? And how should we consider Flash's effect on the revised guidance range? What portion came from Flash and the forthcoming arterial product launch as opposed to neuro?

Adam Elsesser

executive
#7

Yes, Robbie, first, thank you for the — I was about to call it a 2-part question, but actually I believe it's a 3- or 4-part question. Let me attempt to explain it this way. I believe our prepared remarks make clear that we're in quite a favorable position at present. With the Flash launches, the Lightning Bolt 7 launch, and the neuro launches, we're experiencing considerable momentum. Thus, we deliberately stated that purely in numerical terms, the peripheral thrombectomy devices, Flash and LIGHTNING BOLT alike, will play a bigger part in that expansion. Clearly, the figures bear this out. And that's logical considering the 800,000-patient target we've set, which everyone appears to regard as conservative. So that's what we aim for. Regarding the question — the first one about market expansion versus share gain and such, it hinges on which product we mean and how one defines market expansion versus share gain. Clearly, in stroke, we aim to treat an ever-growing number of patients. Yet simultaneously, during the recent period when market growth decelerated, share gain was essentially the main priority; now we're observing somewhat renewed enthusiasm for stroke. There's considerable energy surrounding it. So I believe we'll witness both in stroke. Regarding LIGHTNING BOLT, one could contend, based on how you define share gain versus market expansion, that there aren't really competing mechanical products for the most part. You're discussing alternative procedures, be it open surgery or lytic. Is that share gain from those conditions? Or is it market growth — I'm uncertain whether it matters. That's our primary focus: pursuing those areas where physicians employ those — those approaches to treating those patients. And regarding the venous side, both PE and DVT, it will involve both how quickly share moves and how quickly we then pursue the remaining patients, the DVT patients and the PE. That's truly the task before us this year and next year and the year after as we concentrate our efforts on reaching those 800,000 patients.

Jason Mills

executive
#8

Absolutely. Robbie, regarding the guidance and contribution portion of what you asked, I believe we noted during our prepared remarks that the bulk of that $20 million increase on a sequential basis came from our U.S. vascular thrombectomy business. That, naturally, was mostly Flash. And going forward, as Adam pointed out, we anticipate Flash and Lightning Bolt 7 will account for a comparable portion of the growth we're looking at — that acceleration we expect. A few additional reminders to assist you: we stated that on the venous and PE side, purely in terms of procedural volume, we think we grew more than 30% on a sequential basis versus the fourth quarter within our U.S. venous franchise.

Robbie Marcus

analyst
#9

That's quite useful. Could I possibly slip in one final question? That was likely the strongest quarter you've seen in stroke or neuro for quite a while. How long can that last, and are there any nonrecurring items worth flagging?

Adam Elsesser

executive
#10

Sure. That's a wonderful question. Honestly, there isn't any single distributor order that falls outside the normal cadence. What we pointed to as the actual driver stems from the rollout of — the ongoing rollout of RED across Europe, but more significantly a rather extraordinary rollout of the product we refer to as SENDit, our inner catheter technology designed for RED 72, plus the ongoing rollout of RED 43; we're beginning to receive additional inventory to back that up, and the response has been rather extraordinary. So on top of that, I'd add what we're beginning to observe — and once more, I don't want to curse it by claiming we possess enormous clarity on it, yet we're beginning to observe a rather refreshed enthusiasm among the field regarding treating stroke and returning to the effort required to expand that. So we feel good about it. We believe we're sitting in a rather solid position regarding our stroke business. Yet once more, clearly, the primary subject we've been hearing from nearly everyone this quarter concerns Flash and Bolt. And once more, those products are doing amazingly well and provide us with an enormous degree of confidence. Honestly, it's simply been very enjoyable to watch the cases, to watch the response from customers we've had for many years but additionally the countless customers who aren't — who are unfamiliar with our thrombectomy tools. It's simply very enjoyable.

Jason Mills

executive
#11

Absolutely. To build on Adam's point regarding the excitement surrounding stroke, it's also reasonable to note that the prior-year figures for that segment were somewhat less demanding. Beyond that, we've mentioned independently that while our U.S. vascular thrombectomy unit had a very robust quarter, for the vascular division worldwide as a whole, we anticipate picking up pace as the year progresses, carrying forward the momentum established in Q1 — just to offer context on both aspects.

Larry Biegelsen

analyst
#12

Adam, your remarks about Bolt on the arterial side caught my attention. You folks hold a really commanding spot in that area. Whether meaningful rivalry exists in mechanical thrombectomy, I'm not sure. So my read was that this is more of a possible mix advantage. Yet you mentioned capturing procedures from lytics and from open surgery. On that final slide, the most recent figures you gave showed roughly 50,000 procedures among approximately 260,000 patients, which works out to 20% penetration. So how are you — I suppose, what's your thinking on switching over lytics and open procedures? What's behind that push? And beyond providing a superior product, what else do you figure you'll need to do to make that conversion happen? I also had one follow-up.

Adam Elsesser

executive
#13

Yes. Larry, thank you; that is a truly, truly excellent question. And it's still early, and we will sort of lay out our strategy as we sort of begin carrying it out across the next couple of quarters rather than beforehand. I believe you can appreciate that. But the real — the single most crucial point there is what we described. Should this product keep performing the way it has, and we've completed enough cases to be far beyond fretting that it's — we aren't in the dark. We're certain. If it's as straightforward as inserting the catheter into the clot or ahead of the clot, pressing the button and the clot usually exits rather fast in most of these cases, that is rather persuasive to either an interventionalist or a vascular surgeon who has employed a different method, since that's rather quick. That's rather safe; that's rather simple. And it's sort of generating a response that we're witnessing; now how much time is needed to spread that word so people try it, so people have that identical experience? We'll find out. That's the issue; and clearly, we're concentrating all of our energy, and I've repeated that again and again on the call, on achieving that. But that's really what occurs. Will there be further work for us to do to demonstrate that, to bring people together to exchange that experience? Certainly. But the key thing is the product is performing precisely as we'd hoped it would, and it's receiving a very favorable response especially — we anticipated a favorable response among our existing customers, but among those who otherwise weren't using our tool but instead using either open surgery or lytics, and for me that's what provides the confidence that we have a freely — a lengthy runway with this product.

Larry Biegelsen

analyst
#14

That helps. Only a couple of fast questions — and I do mean fast. First, regarding Flash, is supply no longer an issue for you? And second, about the THUNDER trial, any news on enrollment and your expected finish date.

Adam Elsesser

executive
#15

Sure. Let me begin with THUNDER. We're still enrolling. Cases are progressing nicely. We'll provide a completion-date update when we can, roughly within the coming quarter. What we're noticing is considerably more momentum building around it, and that's genuinely encouraging. I believe that stems from our perception that the markets — attention has returned to stroke and similar areas; we do observe some of the metrics. We're seeing far more screen failures, not because those patients ultimately don't get treated, usually with our product, but because we are — the trials include an 8-hour window; so I'd say that's actually a good sign that there's enthusiasm focused on the ongoing trial; but once more, so far, quite optimistic, and we'll share a more definitive update the moment we have a clearer read on that. On the supply constraint question for Flash, we're in a far stronger position. We've worked extremely hard to get ahead of it. And I don't believe we consider ourselves supply constrained for Flash or Bolt at this stage.

Joanne Wuensch

analyst
#16

A few things I'd like to ask. Let me confirm I have the correct figures. Vascular overall increased 17.2% on a constant currency basis, and in the U.S. it rose 23%. How about OUS?

Jason Mills

executive
#17

For OUS, that figure wasn't provided by us, though it clearly came in below that, below the overall figure, since averages behave that way; and to give you a somewhat wider response on that, the worldwide vascular figure was plainly propelled by the U.S. vascular thrombectomy franchise. That accounted for most of the $20 million rise sequentially in our global quarterly revenue. We noted our U.S. vascular business expanded 23%. I believe we also noted that our U.S. vascular thrombectomy component in particular rose 26% year over year. So what you're observing is momentum building within the vascular franchise along with first quarter strength in terms of growth, setting aside the distributor variance we experienced year over year in vascular internationally, which Maggie referenced; and there was some distributor variance, with vascular having a strong first quarter a year ago across a few distributor markets, and simply the way things trended differently this year caused that distinction, which is why we felt it mattered to highlight the U.S. so you get a genuine picture of growth in that vascular business, where the new products sit.

Joanne Wuensch

analyst
#18

Understood. To build on that, is Thunderbolt still expected to receive approval by the close of the year? And whether it is or isn't, how do you see adoption shaping up for that specific product?

Adam Elsesser

executive
#19

Right. Like I mentioned moments ago in response to Larry, we'll provide a more considered update regarding precisely when that will happen at some point across the coming quarter or so, once we've got a clearer picture, as I noted. Given a refreshed degree of interest surrounding the stroke space, we'd like to let that develop a little before giving you something more precise. Even so, we've consistently stated that we're enthusiastic about that product. We're eagerly awaiting it. In the interim, though, we're putting substantial effort into the stroke area through RED 43 and SENDit. I believe that's a worthwhile use of time to build the groundwork for Thunderbolt. And once more, we're fortunate to already have Flash and LIGHTNING BOLT available today. Taking all of that together, we're currently in a very strong position.

Jason Mills

executive
#20

Correct, and building on what was said, Joanne, to restate that idea, what matters most in this case is the fresh momentum surrounding stroke; plus this newly launched offering, SENDit, is genuinely performing rather strongly at 43; and one more thing worth recalling is that we held no forecast for Thunderbolt revenue in our 2023 guidance, nor do we hold one now. With that noted, SENDit and 43 are doing extremely, extremely well. So that has us enthusiastic.

Imron Zafar

analyst
#21

Jason, the first thing I'd like to ask about is blood loss. A competitor of yours made remarks regarding how your 16 French catheter, also known as Lightning Flash, performs, and mentioned the significant rates of blood loss in their data set. I was just curious, given that you presumably have a much larger data set, what you are observing in your commercial experience, particularly on this blood loss endpoint with Flash.

Adam Elsesser

executive
#22

Yes. Well, thank you for asking. Clearly, among those who use the product regularly, nobody has witnessed that or made any comment about it. And I believe the majority of people get that.

Imron Zafar

analyst
#23

All right. So, regarding gross margin — I believe on the previous call you mentioned 1 to 2 points of improvement versus last year for this year. Yet at this point, with volume leverage working in our favor and inflationary pressure appearing to ease somewhat, I'm curious: does that mean the year-over-year gain will end up meaningfully larger than the 100 to 200 basis points you referenced a quarter ago? Also, what sort of time frame do you envision before reaching that 70% gross margin level?

Maggie Yuen

executive
#24

Appreciate the question. Yes; through the first quarter thus far, the trend looks quite favorable. It's encouraging that every one of the new product launches has added to gross margin. And our productivity progress remains on schedule across the board. Additional opportunities to improve margin are showing up. Over the near term, our main emphasis will be satisfying growing demand and the quality of new product launches. As noted during my prepared remarks, certain higher start-up costs do accompany all these new product launches, yet our objective of 100 and 200 basis point improvement for the year is still on track.

Imron Zafar

analyst
#25

Alright. So then, at what point do you expect — is there a timeline for when you believe you can hit that 70% gross margin goal you've set as aspirational?

Maggie Yuen

executive
#26

Yeah. Over the coming years, we expect to keep benefiting from better mix along with gains in productivity. As a result, within just a few years, we remain on course for that target of 70-plus percent gross margin.

Margaret Kaczor

analyst
#27

I won't attempt to cover everybody the way Larry does, simply because we're short on time, but I do appreciate it. Perhaps the first question, just following up on reorder rates for both new and existing accounts. You said those are climbing. For existing ones in particular, could you help us understand the magnitude of that increase, and maybe how it stacks up against the potential addressable markets within some of these existing accounts? Perhaps you're at 10% out of that 100, something like that.

Adam Elsesser

executive
#28

Yes. So Margaret, I apologize, I didn't completely follow — you're asking, with respect to our existing accounts, how much has that figure risen?

Margaret Kaczor

analyst
#29

Yes.

Adam Elsesser

executive
#30

Yes. Regarding Flash, let's compare it with Lightning Bolt 7. When it comes to Flash, the initial effort during Q1 was, once again, about putting the product in customers' hands, having them place orders and start using it. Because of that, it's difficult to really measure how many folks who would otherwise have been on Lightning 12 were now on Flash, or how many additional cases they treated that they'd have handled with a different option. That group is likely fairly small, so I probably wouldn't have put a number on it. I don't have that figure. What I believe we're focused on is people who adopted our products versus those who hadn't. The ones who hadn't adopted our products — that's arguably the most critical figure. A portion of them relied on alternative approaches, such as lytics. Others turned to different mechanical instruments, devices available on the market. The rates of reuse and reordering are extremely high, and they're consistent across both these new customers and those who had used Lightning 12 previously. And I — we felt it was worth sharing since that's a hugely important fact, one that gives us confidence this is sticky even among customers who hadn't used us prior to this launch. So that's the message we were trying to convey. We aren't observing — I'm certain you could find one individual who didn't follow that pattern, but the overwhelming majority did. And that degree of engagement and reordering matters, both for existing customers but even more so when it comes to growing the new customer base.

Margaret Kaczor

analyst
#31

All right, and from where I sit, I think utilization played a role in that too. We can get into that at another point. For my second question, you brought up the PE, DVT, which went up 30% quarter over quarter. Clearly, that looks like quite a large figure. Could you share any insight into how the January and March compare in terms of scale? And is it possible for that momentum to continue into April and after?

Adam Elsesser

executive
#32

Yeah. The key point to keep in mind is this — once more, without diminishing any of the thrill and eagerness that we or anybody else has, there's nothing 100% linear about these things. I'm certain we'll use much of the time ahead discussing the mechanics of launches and similar topics, since they don't follow a simple, straight-line path; yet it's clear from the guidance we've revised that we hold strong confidence in our ability to pull this off, and that adoption of these products will happen at rather substantial levels throughout this year. That, then, is the central point we hope to get across — that these products are effective. They're fairly — they bring about transformation on a magnitude that isn't commonly encountered. It's quite uncommon. And beyond fretting over this quarter and the one after, what matters is what we've accomplished, what we're capable of doing now, and after speaking with many, many doctors, we're moving nearer to offering products that can reach the market and truly serve as viable treatments for every patient who ought to receive them. That's the task in front of us. That's roughly the priority we, as an organization, can now direct toward these products, thanks to how they've been received up to this point. And that's genuinely thrilling. That's essentially our purpose here — building products capable of clearing clot, whether located in the arteries of your leg, your veins, or your lungs, in a way that comes close to being ordinary. So that's our aim, and I believe we're very near achieving it, and that's the source of the current enthusiasm; so we're getting down to work.

Michael Sarcone

analyst
#33

Alright, a fast follow-up relating to what Margaret asked. You mentioned PE and DVT procedures growing more than 30% quarter over quarter. Could you share anything about how that compared year over year?

Jason Mills

executive
#34

It was meaningful, though those figures aren't right in front of me. It was meaningful. Clearly, our fourth quarter was fairly strong, and Q4 typically ranks among our best quarters. So I believe we haven't cited that figure, and I don't have it here with me, but for that business and for the vascular business — the U.S. vascular thrombectomy business, as we stated — growth year over year was meaningful. So a reasonable way to describe it is that it exceeded the figure we provided for the entire U.S. thrombectomy business.

Michael Sarcone

analyst
#35

All right, that's useful. So then I was simply wondering — for Lightning Bolt in arterial, regarding the docs use case, you mentioned how it's fast, safe, and easy. Could you also describe how the economics work when someone chooses Bolt instead of open surgery or lytics?

Adam Elsesser

executive
#36

Sure, that's a really solid question when it comes to Lightning Bolt 7. Things differ — if you only consider material cost, clearly Lightning Bolt costs more than what a "materials cost" approach in open surgery would run. Yet when you view it the way the majority of hospital administrators do, factoring in the hospital's total cost, the OR, which a lot of them get billed for roughly per hour, plus the post stay and its duration, comparing those open surgeries with interventional ones, and the same for lytic — 2 days in ICU on average — we can make a fairly strong case that on a total cost basis we're substantially more cost-effective than either of those 2. So I believe we'll gain some genuine traction. Once more, the initial step is getting everybody to order it, work through it, and give it a try. What excites me is that, much like Flash, there's considerable interest in it. There's a lot of — we're not — there will be a segment we likely need to persuade. Still, up to now, we've had substantial momentum with people ready to work with us through the process to get the product moving, in, and into use; and once again, that stems from the successful cases we witness daily.

Shagun Singh Chadha

analyst
#37

Nice work on the quarter. I was hoping to get a bit of clarity. What caught my attention was that the upside versus what people expected came from neurovascular rather than peripheral. You also mentioned that U.S. thrombectomy adoption seemed stronger than what we had anticipated, at minimum. So on the vascular side, was there anything offsetting that we should factor in, whether overseas or somewhere else? Then regarding guidance, to clarify as well, I wanted to ask how much of Bolt is included in guidance? Does Flash account for most of the guidance raise? You noted there isn't much for Thunderbolt in there, but what about LIGHTNING BOLT? How much of that is included? And I have one more question after that.

Jason Mills

executive
#38

Yes. Thanks, Shagun. Jump in if I left anything out, but I'll do my best to cover both the vascular topic and the guidance topic. So starting with vascular, the way I see it, I don't believe — I agree with how you framed it. I realize it appears neuro provided the upside relative to the consensus numbers you all had, but we never issued guidance broken out between neuro and vascular; and the U.S. vascular business did come in above what you had modeled. On the international side, like Maggie said, distributor variances worked in neuro's favor and the reverse worked in vascular's favor, which is the reason we highlighted our U.S. vascular business and our U.S. vascular thrombectomy business, so you can gauge that; and we also noted that Flash accounted for most of that $20 million sequential gain. So when you combine those points, I think what you conclude is that U.S. vascular thrombectomy powered the quarter's strength. When it comes to the guidance, definitely, like Adam said, looking ahead, we've stated that our vascular business is going to accelerate. We've also indicated that vascular growth worldwide will come in a bit above the upper bound of that global revenue guidance range. That ought to give you, I believe, sufficient guidance to reach the conclusion that Flash and Bolt are going to account for a meaningful share of the growth we see year-over-year, which in dollar terms year-over-year now sits at roughly $200 million.

Shagun Singh Chadha

analyst
#39

Understood. Next, regarding what you've said here, you've discussed your product lineup during 2023 and described those items as transformational. Your guidance points to 24% growth for 2023. So I'd like to know what that implies for how your sales could grow after 2023. Should we view you as a company expanding at roughly 20%, give or take? Any minimum threshold you'd be comfortable sharing? Also, on the margin side, you mentioned finishing at above 10%. For 2024, ought we to expect an increase of comparable size to what we witnessed in 2020 — and what we anticipate for 2023?

Jason Mills

executive
#40

I'm genuinely grateful for those questions. It delights me that you're already attempting to extract 2024 guidance from us. I have enormous respect for that. Even so, my feeling is that providing 2024 guidance is premature right now. Naturally, we've invested significant effort examining how our business will look, and not only during 2024. Adam may have referenced 3 or 4 instances of 5-plus years; so obviously, those remarks weren't made carelessly but rather came after substantial discussion with our whole team regarding what this year and that 5-plus-year period will bring. Moreover, we anticipate robust growth ahead, robust double-digit growth, though without attaching any kind of quantitative figure to it at this point. Regarding operating income, my sense is that we deliberately made a qualitative effort to convey that we — given robust revenue growth, our expectations for gross margin expansion, and the disciplined spending we practice — do anticipate our operating margins will expand both this year and the following year; and to express that quantitatively, once more, it's somewhat premature, yet we're enthusiastic about the leverage present in 2024 and honestly past that.

Bill Plovanic

analyst
#41

A few points. First, right now in this launch, do you believe Lightning Flash and Bolt have reached every account? On the previous call, I believe you were still in the LMR stage with Bolt. Following up on that, are you noticing the Bolt rollout or its benefits picking up speed? I recall we discussed approaching the VAC committees with both products simultaneously. I'm just trying to get a sense of where things stand in the launch at this point.

Adam Elsesser

executive
#42

Yes. Regarding LIGHTNING BOLT, we brought the product to market. When was it? May 2, we released it roughly 3 weeks ago, something in that range. I've lost precise track of the timing. So you can feel fairly sure that we haven't reached every single account across the United States with it and gotten it onto shelves yet. That would be incredible; it requires time. As you've heard, one of the biggest systems in the nation just signed Flash to a contract, which lets us begin working with the individual hospital VAC committees at each of their hospitals; that happened in April, and we launched that back in January. So this process takes time. Even so, we're quite excited about how it's been received; and absent a positive reception, you could have all the time in the world, nobody would care. People do care. They're enthusiastic about it. And I think we deliberately took pains on this call to make clear that these products have a fairly long tail, and that's quite exciting for us. And I think, hopefully, our physicians and the customers will get the product.

Bill Plovanic

analyst
#43

Great. And if I may ask about the real product — with the agreement you just announced with the VA for real — how should we think about what this product brings in, both in the near term and further out? Should it — do we sort of put it back into the conversation, or do we still wait, maybe until next year, before we really start considering it?

Adam Elsesser

executive
#44

Yes. A great deal of work remains to be done. I'm eager to tell you about some of what's going on there. Certain parts we'll be in a position to discuss; other parts, I'm not able to discuss at this point. Honestly, I have a lot of confidence and enthusiasm about locating this partner, about discovering how much they care about this mission, and about the opportunity — which is now actually a reality — to assist a large number of veterans, and that in turn lets us build a model we can expand across the entire country. So this makes me quite excited and quite hopeful. Still, when you look at it as far as bringing in revenue, especially during a year like this one when we've got Lightning Bolt 7 and Lightning Flash within our neuro business, this won't be the subject we focus on when discussing revenue. Yet as far as preparing the foundation for what's ahead, the timing right now is ideal.

Richard Newitter

analyst
#45

I just wanted to ask, as a follow-up to something asked earlier — that question — you posted 30% growth quarter over quarter, as I understand it, in your thrombectomy — venous thrombectomy; and I'm curious how much of that perhaps derived from March. The launch, as I understand it, didn't span the whole quarter, or wasn't at full scale for all of it; so could you describe that for us?

Adam Elsesser

executive
#46

Sure. Well, here's what we stated — and I want this to be completely unambiguous; we stated a 30% rise in procedures performed. Clearly, we're shipping product. Orders are coming in. We were quite clear that procedures were the subject, and that's a key detail. We also noted that acceleration was occurring across the quarter. So from that you'd gather March outperformed February, and February outperformed January. And I believe it's quite evident that momentum exists for this product.

Richard Newitter

analyst
#47

All right, that's useful. So regarding the range you gave us — I appreciate it — the guidance of $1.04 billion to $1.06 billion, I'm simply wondering whether you could share any benchmarks for how those upper and lower bounds were derived. What would it take to reach the top end? I'm aware someone brought up Bolt and contribution there. It sounds like Bolt is included. But I'd really like to hear how you arrived at that figure.

Jason Mills

executive
#48

Yes. Well, our business is something we understand very well. We've provided guidance for 8 years at this point. I don't want to sound like that, but it's worth pointing out. And many factors get factored in. As for our vascular business, growth slightly quicker than that is what we anticipate, while our neuro business comes in a little bit under that. We put in a lot of effort on this and reached this conclusion. Clearly, it's accelerating growth for the year and a lot higher than what we did in the first quarter; so we feel good about where we are now with that guidance.

Mike Matson

analyst
#49

I'd like to ask just one thing regarding the Value Analysis Committee process. Roughly what's the usual length of time it takes? How open have they been to Flash and Bolt? Also, do they request data? What I mean is, I don't believe you have a great deal of human data available on these products, but...

Adam Elsesser

executive
#50

Yeah. That's an excellent question. At some point, I ought to — we ought to hold a small class about how these products — these items get launched and sold, and so forth. This process is fairly varied. Certain hospitals are quite simple. Others aren't. Often the largest problem is getting the meeting scheduled. I could run through every sort of thing. None of those serve as excuses; we're doing well; this is functioning. I just — there's a gate right here that everybody simply needs to keep in mind. You cannot simply sell to every person who wants it right away. And that process is just — we're bringing it up plainly to remind everybody that a process exists here; having said that, yes, things are working quite well. The physicians act as advocates. They want us — they want the product. We understand how to navigate this; we've been selling product now. The company has for well over a decade, and we understand how to accomplish this; and so there's nothing out of the ordinary about this process compared with any other product that we've ever launched, and we launched dozens and dozens and dozens of products over the course of the year. So nothing apart from the process. It means we must go through it over time.

Mike Matson

analyst
#51

All right, that makes sense. Then I have one final thing about China. I'm just wondering — I didn't catch any mention of that market during the quarter. And I'm also curious whether you're noticing any effect from the VBP situation there.

Jason Mills

executive
#52

Yeah. Appreciate that question, Mike. Yeah, we definitely, similar to other businesses, have watched the VBP process begin to unfold. And it's unfolding the way we anticipated. I simply need to repeat that our partnership with Genesis matters a lot. Things are going quite well; it's still relatively early in general regarding which products we're partnering with them on, both on the neuro side and the vascular side. So taking all of that into account, I believe China's future looks bright for Genesis and, as a result, for us as their partner.

Samantha Kurtz

analyst
#53

Sam here, filling in for Matt. One thing we wanted to revisit — you brought up the reorder rate. Could you give us a bit more detail, and perhaps frame it against earlier launches?

Adam Elsesser

executive
#54

On the historical comparison, it varies — with all the products we've released across the years, doing that reliably is tough. Think about Lightning 12; that may be the strongest comparison, and the reorder rate among new customers looks greater. The figures aren't in front of me, so I can't give you a precise quote. If I actually had that figure on hand, you'd suspect something was off that I'd carry it around in my head. I simply don't; but the thing that truly pleased us is how this product has been received and how customers who hadn't been using our products previously reordered it since they genuinely liked it; and that's a key metric for us to put forward so that, you know, when we issue guidance and discuss it, what underpins it and how confident we are that across the coming years, we can reach all these patients. That's the reason we raised it. Clearly it's something markedly above what we've seen before, but putting a number on it isn't possible because I don't have — among the dozens of products we've brought to market, I don't know that.

Ryan Zimmerman

analyst
#55

I assure you this won't be a 30-part question crammed into a single one. It'll be a single question crammed into a single question, so — I just want to touch on Lightning Flash for a moment. One thing we never discussed was pricing; and I realize you won't provide pricing figures, Adam, but I would really like you to describe, in a qualitative way, how unit growth compares with pricing as Lightning Flash gets commercialized, plus what effect pricing might have on that unit growth or the market expansion, and how significant that is to what you're suggesting within your guidance.

Adam Elsesser

executive
#56

Yes. Truly — I genuinely appreciate that question. It's an excellent one. Some inaccurate information has been circulating regarding our pricing. What we did was set Flash's price below what was, at that time, the market-leading price. If you compare Flash with Lightning 12 and factor in the need for a separator, the price isn't fundamentally different. The two are extremely close in price — not identical, yet near enough that you won't observe meaningful gain merely from mix or price between the two. So this represents genuine gain. These are products being utilized in cases that otherwise we wouldn't necessarily have taken on. And that matters greatly here. Our price isn't — this isn't entirely price gain coming from existing customers. Actually, it's a very, very small portion of the mix, if any at all. Once more, we haven't put a number on it.

Jee Hamlyn-Harris

executive
#57

Thanks, operator. Our management team and I want to express our appreciation once more for everyone being here with us today and for the attention you're giving Penumbra. We're eager to share our progress with you on the call for the second quarter.

Operator

operator
#58

This concludes today's conference call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.